<p><sup>a</sup> 7 men eligible for HVTN 503-S did not have a circumcision assessment after enrollment in Phambili.</p><p><sup>b</sup>Differences in enrollment between those who completed Phambili follow-up and those who discontinued early were also statistically significant within gender subgroups (all p-values < 0.001).</p><p><sup>c</sup> Two participants were missing HSV-2 data at enrollment in Phambili.</p><p><sup>d</sup> Differences in enrollment between vaccine and placebo groups overall or within subgroups were not statistically significant, except for Soweto (p = 0.045) and Cape Town (p = 0.03); the p-value for circumcised men was 0.054.</p><p>HVTN 503-S contact disposition for eligible Phambili participants (N = 695).</p
Increased coverage of voluntary medical male circumcision (VMMC) is needed in countries with high HI...
Despite compelling evidence linking voluntary medical male circumcision (VMMC) with 60–70% HIV risk ...
Background: The HVTN 503/Phambili trial, a phase IIB study of the Merck Ad-5 HIV vaccine, suspended ...
subtype B HIV-1 preventive vaccine vs placebo in sexually active HIV-1 seronegative participants in...
The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the...
Background: New prevention options will be added to the 'standard of prevention' offered in HIV vacc...
Overwhelming evidence, including three clinical trials, shows that male circumcision (MC) reduces th...
BACKGROUND: Overwhelming evidence, including three clinical trials, shows that male circumcision (MC...
BACKGROUND: The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and eff...
BackgroundClinical trials have clearly shown a reduction in HIV acquisition through voluntary medica...
Flow of participants through the voluntary medical male circumcision (VMMC) programme among adult me...
Despite compelling evidence linking voluntary medical male circumcision (VMMC) with 60–70% HIV risk ...
Genital human papillomavirus is one of the most common sexually transmitted infections and a signifi...
Early diagnosis of HIV and treatment initiation at higher CD4 counts improves outcomes and reduces t...
PrePex Male Circumcision (MC) has been demonstrated as an effective and scalable strategy to prevent...
Increased coverage of voluntary medical male circumcision (VMMC) is needed in countries with high HI...
Despite compelling evidence linking voluntary medical male circumcision (VMMC) with 60–70% HIV risk ...
Background: The HVTN 503/Phambili trial, a phase IIB study of the Merck Ad-5 HIV vaccine, suspended ...
subtype B HIV-1 preventive vaccine vs placebo in sexually active HIV-1 seronegative participants in...
The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the...
Background: New prevention options will be added to the 'standard of prevention' offered in HIV vacc...
Overwhelming evidence, including three clinical trials, shows that male circumcision (MC) reduces th...
BACKGROUND: Overwhelming evidence, including three clinical trials, shows that male circumcision (MC...
BACKGROUND: The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and eff...
BackgroundClinical trials have clearly shown a reduction in HIV acquisition through voluntary medica...
Flow of participants through the voluntary medical male circumcision (VMMC) programme among adult me...
Despite compelling evidence linking voluntary medical male circumcision (VMMC) with 60–70% HIV risk ...
Genital human papillomavirus is one of the most common sexually transmitted infections and a signifi...
Early diagnosis of HIV and treatment initiation at higher CD4 counts improves outcomes and reduces t...
PrePex Male Circumcision (MC) has been demonstrated as an effective and scalable strategy to prevent...
Increased coverage of voluntary medical male circumcision (VMMC) is needed in countries with high HI...
Despite compelling evidence linking voluntary medical male circumcision (VMMC) with 60–70% HIV risk ...
Background: The HVTN 503/Phambili trial, a phase IIB study of the Merck Ad-5 HIV vaccine, suspended ...